FDA grants priority review to Merck-Daiichi’s B7-H3 cancer ADC
FDA grants priority review to Merck-Daiichi’s B7-H3 cancer ADC
Body unavailable. Use the original source.
FDA grants priority review to Merck-Daiichi’s B7-H3 cancer ADC
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.